Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

RSV Vaccine Recommendations

Adult RSV Vaccination

  • The American College of Physicians recommends RSV vaccination for adults aged ≥60 years and those aged 50-59 years with risk factors, such as chronic respiratory conditions, cardiovascular disease, diabetes, chronic kidney or liver disease, immunocompromised status, frailty, dementia, or residence in nursing homes 2, 3, 4, 5
  • Adults aged 50-59 years with risk factors should receive RSVPreF3, the only approved vaccine for this age group 2, 4
  • RSV vaccination for adults should preferably be administered between September and November, though it can be given at any time 2, 4
  • The vaccine can be co-administered with seasonal influenza vaccines at different injection sites 5, 4
  • RSVPreF3 has demonstrated maintained efficacy for at least three seasons in adults aged ≥60 years 4
  • RSVpreF has shown maintained efficacy for at least two seasons in adults aged ≥60 years 4

Pediatric RSV Protection

  • The American Academy of Pediatrics recommends two main options for RSV protection in infants: maternal RSVpreF vaccination during pregnancy and nirsevimab (monoclonal antibody) administration to the infant 7, 8, 9, 10
  • Maternal RSVpreF vaccination is recommended as a one-time dose during 32-36 completed weeks' gestation and should be administered seasonally (September through January in most of the continental US) 7, 8, 9
  • Nirsevimab is recommended for infants aged <8 months who are born during or entering their first RSV season, and for all infants born at <34 weeks' gestation regardless of maternal vaccination status 7, 10
  • Nirsevimab may be considered in addition to maternal vaccination in rare circumstances when incremental benefit is warranted, such as in infants born to immunocompromised mothers or those with substantially increased risk for severe RSV disease 10

Special Considerations

  • The National Comprehensive Cancer Network recommends consultation with infectious disease specialists for cancer patients, as the effectiveness of RSV vaccines is unknown in this population 1, 6
  • When administering multiple vaccines concurrently, use different injection sites, and no clinically significant interference has been established between RSV and influenza vaccines, though some studies show numerically lower antibody titers 5, 4

REFERENCES